InMed Pharmaceuticals (INM) EBIAT (2021 - 2025)
Historic EBIAT for InMed Pharmaceuticals (INM) over the last 5 years, with Q3 2025 value amounting to -$1.7 million.
- InMed Pharmaceuticals' EBIAT fell 158.23% to -$1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.2 million, marking a year-over-year decrease of 1981.13%. This contributed to the annual value of -$8.2 million for FY2025, which is 649.35% down from last year.
- Latest data reveals that InMed Pharmaceuticals reported EBIAT of -$1.7 million as of Q3 2025, which was down 158.23% from -$1.8 million recorded in Q2 2025.
- InMed Pharmaceuticals' EBIAT's 5-year high stood at -$338391.0 during Q2 2023, with a 5-year trough of -$7.9 million in Q2 2022.
- Moreover, its 5-year median value for EBIAT was -$2.1 million (2022), whereas its average is -$2.6 million.
- Its EBIAT has fluctuated over the past 5 years, first skyrocketed by 9570.03% in 2023, then plummeted by 47983.84% in 2024.
- InMed Pharmaceuticals' EBIAT (Quarter) stood at -$4.3 million in 2021, then surged by 50.94% to -$2.1 million in 2022, then increased by 29.65% to -$1.5 million in 2023, then tumbled by 74.2% to -$2.6 million in 2024, then soared by 32.94% to -$1.7 million in 2025.
- Its EBIAT stands at -$1.7 million for Q3 2025, versus -$1.8 million for Q2 2025 and -$2.1 million for Q1 2025.